A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6)

NCT02576665 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

21

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor decision

Conditions

Colorectal Cancer
Triple Negative Breast Cancer
Pancreatic Cancer
Non-Small Cell Lung Cancer
Head and Neck Cancer
Ovarian Cancer
Lymphoma
Sarcoma
Bladder Cancer
Melanoma
IDH1 Mutated Solid Tumors
IDH1 Mutated or MGMT Methylated Recurrent HGG (Not Recruiting)

Interventions

BIOLOGICAL: Toca 511
DRUG: Toca FC

Sponsor

Tocagen Inc.